CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today the treatment of the first patient in its CR011-vcMMAE Phase II breast cancer study. The Phase II trial is an open-label, multi-center study of CR011-vcMMAE administered intravenously once every three weeks to patients with locally-advanced or metastatic breast cancer who have received prior therapy.

More: continued here

This entry was posted on Monday, June 30th, 2008 at 10:06 am and is filed under Breast Cancer. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.